WashU Experts: The First 100 Days

WashU Experts: The First 100 Days

America spoke in November, one month after the candidates collided in the presidential debate held Oct. 9 at Washington University in St. Louis. In the days that followed the historic 2016 election, faculty experts across campus offered their perspectives on the economy, the legislative responses, the cultural and global ripple effects.
WashU Expert: Gorsuch best possible choice under circumstances

WashU Expert: Gorsuch best possible choice under circumstances

Neil Gorsuch, President Donald Trump’s nominee to fill the vacant seat on the U.S. Supreme Court, has a strong commitment to rule of law values and is the best possible choice among the potential nominees that Trump circulated before the election, says a Supreme Court scholar at Washington University in St. Louis.
WashU Expert: Trump has no clear plan for reducing drug prices

WashU Expert: Trump has no clear plan for reducing drug prices

Despite announcing in his first press conference that he would deal with a pharmaceutical industry “getting away with murder,” President-elect Donald Trump doesn’t seem to have a clear path for how he will reduce drug prices, said Rachel Sachs, associate professor of law and expert on drug regulation and health law.
Helping rebuild Nepal after an earthquake

Helping rebuild Nepal after an earthquake

In 2014, Marla Borkson volunteered in Nepal for five months. When an earthquake hit in April 2015 while she was in the middle of her 1L year at Washington University, Borkson knew she had to act. She spent her summer in Nepal helping citizens in rural Nepal get health treatments.

Memorial service Dec. 1 for Teitelman

A memorial service for Richard Teitelman, JD ’73, and judge on the Missouri Supreme Court, will be held at 2 p.m. Thursday, Dec. 1, in Graham Chapel. Read more about Teitelman on the School of Law site.
WashU Expert: Cures Act’s controversy continues

WashU Expert: Cures Act’s controversy continues

The 21st Century Cures Act, the vast bill aimed at bolstering medical research and revamping the way drugs are approved, is a step in the right direction but is far from perfect, says an expert on the health care industry at the School of Law at Washington University in St. Louis.
View More Stories